Fairmount Healthcare Fund II L.P., Director at Crescent Biopharma, bought CBIO on Jul 16, 2026
Data as of Oct 16
▲ BUY$12.4M853,450 shares at $14.50Fairmount Healthcare Fund II L.P. DirectorCBIO Crescent Biopharma, Inc.
- Traded
- Jul 16, 2026
- Disclosed
- Jul 20, 2026
- Filed
- 4 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
CBIO since disclosure
−21.3%
Similar stocks (XLV) since disclosure
+11.0%
XLV — its sector index fund
Change in closing price from Jul 20, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
- Not enough evidence · In past tests: 8.0 percentage points better than similar stocks over 3 months · 2,952 tries
Other trades in the same filing
- ▲ BUYFairmount Funds Management LLC DirectorCBIO Crescent Biopharma, Inc.$12.4Mdisclosed Jul 20 · filed 4 days after the trade 1 rule fired
- ▲ BUYPeter Evan Harwin DirectorCBIO Crescent Biopharma, Inc.$12.4Mdisclosed Jul 20 · filed 4 days after the trade 1 rule fired
- ▲ BUYTomas Kiselak DirectorCBIO Crescent Biopharma, Inc.$12.4Mdisclosed Jul 20 · filed 4 days after the trade 1 rule fired